Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05831085 · ClinicalTrials.gov registry record · NA
Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease
A NA study of Coronary Artery Stenosis, sponsored by Duk-Woo Park, MD.
- Recruiting
- Registry status
- NA
- Development phase
- 1,500
- Enrollment target
- 20
- Study locations
NCT05831085 is a NA study of Coronary Artery Stenosis that is actively recruiting participants, run by Duk-Woo Park, MD. The registered enrollment target is 1,500 participants, above the 1,292-participant average among 4 other Coronary Artery Stenosis trials with a reported enrollment target (16% higher). The trial reports 20 study locations across 2 states.
The verdict
NCT05831085, a NA study of Coronary Artery Stenosis, is actively recruiting participants, sponsored by Duk-Woo Park, MD.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objective of this randomized study was to compare outcomes of imaging-and physiology-guided state-of-the-art percutaneous coronary intervention (PCI) to coronary artery bypass grafting (CABG) in patients with diabetes and three-vessel CAD (not involving left main).
Conditions Studied
Interventions
- PROCEDURE State-of-the-Art Percutaneous Coronary Intervention
- PROCEDURE standard CABG
Study Locations (20)
Other
- Fuwai Hospital, Chinese Academy of Medical Sciences (CAMS) - Beijing
- Second Affiliated Hospital of Zhejiang University School of Medicine - Hanzhou
- Medanta - The Medicity - Gurugram
- Fortis Escorts Heart Institute - New Delhi
- Sarawak Heart Centre - Kota Samarahan
- University Clinical Center of Serbia - Belgrade
- National Heart Centre Singapore (NHCS) - Singapore
- Daegu Catholic University Medical Center - Daegu
- Keimyung University Dongsan Medical Center - Daegu
- Yeungnam University Medical Center - Daegu
- Chungnam National University Hospital - Daejeon
- Konyang University Hospital - Daejeon
- Gangneung Asan Hospital - Gangneung
- Chonnam National University Hospital - Gwangju
- National Health Insurance Service Ilsan Hospital - Ilsan
- Gachon University Gil Hospital - Incheon
- Dong-A Medical Center - Pusan
- Asan Medical Center - Seoul
- Hanyang University Seoul Hospital - Seoul
California
- Palo Alto VA Medical Center - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2024-06-14 |
| Est. Completion | 2027-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05831085
The ClinicalTrials.gov registry entry for NCT05831085 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,292-participant average among 4 other Coronary Artery Stenosis trials with a reported enrollment target (16% higher). The listed sponsor is Duk-Woo Park, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Coronary Artery Stenosis appearing as the primary indexed condition, and to 2 interventions - of which State-of-the-Art Percutaneous Coronary Intervention is the first listed.
NCT05831085 reports 20 study locations spanning 2 distinct geographic areas - top geographies include Other, California.
Frequently Asked Questions
What is clinical trial NCT05831085 about?
NCT05831085 is a clinical study titled "Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease". The objective of this randomized study was to compare outcomes of imaging-and physiology-guided state-of-the-art percutaneous coronary intervention (PCI) to coronary artery bypass grafting (CABG) in patients with diabetes and three-vessel CAD (not involving left main).
What is the current status of trial NCT05831085?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,500 participants. The study started on 2024-06-14. Estimated completion is 2027-12.
What conditions does trial NCT05831085 study?
This clinical trial studies the following conditions: Coronary Artery Stenosis.
What interventions are being tested in trial NCT05831085?
The interventions under investigation include: State-of-the-Art Percutaneous Coronary Intervention (PROCEDURE), standard CABG (PROCEDURE).
Who is sponsoring clinical trial NCT05831085?
This trial is sponsored by Duk-Woo Park, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05831085 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Stenosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacokinetics of Everolimus in Absorb BVS in Patients With Coronary Artery Lesions
COMPLETED · NA
-
Kidney Damage in Patients With Normal eGFR
COMPLETED · Phase 4
-
A Clinical Evaluation of the MINI TREK RX 1.20 mm Coronary Dilatation Catheter in Stenotic Lesions
COMPLETED
-
XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort)
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.